CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 589 enrolled
Drug / intervention
Aliskirendrug
Likely dose
Aliskiren 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01570686
NCT01570686Phase 4Completed
CompareCT.gov

An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension

Novartis Pharmaceuticals·interventional·Posted Apr 4, 2012·Updated Jan 22, 2014

In Brief

A Phase 4 clinical trial evaluating Aliskiren for Hypertension. Completed, enrolled 589 participants across 83 sites in 7 countries.

Detailed Summary

The purpose of this study is to evaluate the effect of food on aliskiren's efficacy, pharmacokinetics and safety following an oral dose of 300 mg, given once daily under light meal versus fasted conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCanada, Italy, Puerto Rico, Slovakia, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 4, 2012
Enrollment StartApr 1, 2012
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.2 years ago

Interventions

Aliskirendrug

Aliskiren 300 mg once daily